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Abstract
Ageing is a complex process and a broad spectrum of physical, psychological, and 
social changes over time. Accompanying diseases and disabilities, which can interfere 
with cancer treatment and recovery, occur in old ages.  MicroRNAs (miRNAs) are a 
set of small non-coding RNAs, which have considerable roles in post-transcriptional 
regulation at gene expression level. In this review, we attempted to summarize the cur-
rent knowledge of miRNAs functions in ageing, with mainly focuses on malignancies 
and all underlying genetic, molecular and epigenetics mechanisms. The evidences in-
dicated the complex and dynamic nature of miRNA-based linkage of ageing and cancer 
at genomics and epigenomics levels which might be generally crucial for understanding 
the mechanisms of age-related cancer and ageing. Recently in the field of cancer and 
ageing, scientists claimed that uric acid can be used to regulate reactive oxygen spe-
cies (ROS), leading to cancer and ageing prevention; these findings highlight the role of 
miRNA-based inhibition of the SLC2A9 antioxidant pathway in cancer, as a novel way to 
kill malignant cells, while a patient is fighting with cancer.
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Introduction
Ageing is a complex process and a broad 
spectrum of physical, psychological and social 
changes over time (1). It has been determined 
as one of the admitted risk factors for most of 
the human age-related diseases such as cancer, 
leading to approximately 100,000 people deaths 
around the world per day (2). Most of the disease 
and disability, which may interfere with cancer 
treatment and recovery, occur in old ages. Ne-
oplasm is an undiscerning disease that can af-
fect any part of the body of the human being. 
Roughly one third of the people are at risk to get 
cancer in their life (3). However, the incidence 
of cancer is greatly increased in an age-depend-
ent manner. It is reported that around 60% of 
all cancers happen in people aged 65 years or 
above (2). Several molecular mechanisms have 
linked ageing and cancer together (4).
Micro-RNAs (miRNAs) are a set of small 
non-coding RNAs with considerable roles in 
post-transcriptional regulation at gene expres-
sion level. Recent studies revealed that miR-
NAs are involved in many important biological 
processes such as proliferation, differentiation, 
angiogenesis, and immune response. miRNAs 
are generally divided into two categories: the 
first category acts as cytoplasm mRNA inhibi-
tory (e.g. miRNA-451, miRNA-31, and miR-
NA-150) and the second one targets nuclear 
gene transcription directly (e.g. miR-211) (5-
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7). Thus far, numerous miRNAs have been re-
ported to be involved in different types of ma-
lignancy, such as gastric cancer, highlighting 
them as potential treatment targets (8, 9).
In this review we attempted to summarize the 
current knowledge of miRNAs in ageing with 
mainly focus on malignancies and all underly-
ing genetic, molecular and epigenetic mecha-
nisms.
miRNAs and their biogenesis 
miRNAs are highly conserved RNA mole-
cules in the cell that regulate gene expression 
through an interference pathway (10). RNA 
interference (RNAi) is the post-transcriptional 
silencing mechanism in eukaryotes that induces 
degradation of homologous mRNA through cre-
ating double stranded RNA (11).  miRNAs often 
bind to the 3'UTR region of the target mRNA, 
which directs the inhibition of its translation 
or degradation (12). For example, the prod-
uct of Lin-4, controlling genes in Caenorhab-
ditis elegans (C. elegans), is a 22 nucleotides 
RNA that is produced by a 60 nucleotides hair-
pin precursor, and inhibits translation of Lin-
14 through interaction with the 3'UTR of this 
mRNA (10). Distribution of miRNA regions in 
the human genome is in single or cluster form. 
Some of these regions, at least half of them, are 
presented in certain transcription units, such 
as introns and exons (13). miRNA biogenesis 
takes place in the nucleus and cytoplasm, while 
the primary miRNAs, transcribed and poly-
adenylated by RNA polymerase II, are several 
kilo-bases (Kbs) (5). Stem-loop structure of this 
transcript is recognized by a 650 kDa enzyme 
complex that is presented in the nucleus (14). 
This complex contains class 2 of the RNase III 
enzymes, called Drosha, which is specialized to 
cut a double-stranded RNA, as well as a RNA 
binding protein named DGCR8/Pasha (15). In 
the cytoplasm, another RNase enzyme (called 
Dicer) activity leads to generation of the ma-
ture miRNAs. Functionally, Dicer cleaves the 
terminal loop of pri-miRNA and produces dou-
ble stranded 19-22 nucleotide miRNAs (16). 
Usually only one strand of the mature miR-
NAs, known as the guide strand, enters into 
the micro-ribonucleoprotein complex and cre-
ates a micro-RNA-induced silencing complex 
(miRISC), where the sequence of this strand 
determine binding region at the target mRNA 
(17, 18). Since only one of the double strands 
has the ability to play the guidance role for di-
recting the RISC to the 3'UTR region of the tar-
get mRNA, the second strand is deleted. RISC 
binding miRNAs pair to the 3'UTR region of 
the target mRNA homologous and control gene 
expression by inhibiting the cleavage or transla-
tion of mRNA targets (19, 20). About one-third 
of the human genome is considered as potential 
regulatory targets by the several hundred miR-
NAs encoded in the genome. Such regulation 
happens post-transcriptionally and comprises 
the interaction of miRNA with the mRNA target 
site (Fig.1).
Fig.1: microRNA and inhibiting gene expression. 
Mammalian target of rapamycin signaling 
pathway
The mammalian target of rapamycin (mTOR) 
signaling pathway integrates inputs from both 
intracellular and extracellular signals to regu-
late different cellular processes including 
proliferation, growth, survival, motility, au-
tophagy, protein synthesis and metabolism. 
mTOR is a downstream effector of the PI3K/
AKT pathway and consists of two biochemical-
ly distinct complexes, including mTORC1 and 
mTORC2. mTORC1 promotes anabolism, such 
as cell cycle progression, and inhibits catabo-
lism by blocking autophagy. Signaling of this 
complex contributes to tumorigenesis through 
its major downstream targets and key regula-
tors, namely 4E-BPs. It has been demonstrated 
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that mTORC2 regulates cell survival, prolifera-
tion and metabolism. Furthermore, mTORC2 is 
responsible for phosphorylation and activating 
AKT, which may drive tumorigenesis (21, 22). 
Recent studies have revealed different roles 
for mTOR in modulating lifespan, considering 
two processes that mTOR regulates, including 
protein synthesis and autophagy (23). Another 
study reported that mTOR is increased in as-
sociation with BMAL1 deficiency, a transcrip-
tion factor and core component of an internal 
time-keeping system called circadian clock. 
This event eventually contributes to premature 
aging and reduced lifespan (24). Wide-ranging 
researches have indicated that miRNAs-based 
regulation of the mTOR pathway plays a key 
role in cancer progression, and this pathway is a 
promising target by miRNAs for novel antican-
cer therapies (21). Jin et al. (25) in a study on 
the animal model identified a panel of 63 miR-
NAs during dermal wound healing, including 
miRNA-99 family (miRNA-99a, miRNA-99b, 
and miRNA-100). They demonstrated that miR-
NA-99 family members regulate AKT/mTOR 
signaling by targeting several genes such as 
IGF1R. Grundmann et al. (26) screened miR-
NAs involved in adaptive blood vessel growth 
following arterial occlusion. They showed that 
inhibition of miRNA-100 could be a novel ap-
proach for the modulation of mTOR-dependent 
processes, such as blood vessel growth. A grow-
ing body of evidences suggests that miRNAs 
may play a crucial role in cancer therapy and 
diagnosis, which mostly performed through the 
mTOR signaling pathway (Table 1).
miRNAs link with cellular senescence, ageing 
and cancer
Well understanding of the cancer molecular 
mechanisms pathogenesis and active targeted 
therapies are necessary to improve patient treat-
ment outcomes. miRNAs act as key components 
in cancer progression and as the potential thera-
peutic agents or targets. Numerous studies have 
suggested that miRNAs inhibit tumor proliferation 
and promote cellular senescence or ageing, but its 
function has yet to be elucidated. Other studies re-
ported that miRNAs repress global translation, cell 
proliferation and initiates premature senescence 
(Table 2). 
miRNAs, ageing and epigenetics
Ageing is a potent predictor of survival rate 
in cancers, while the biological mechanisms 
for the variation in clinical outcome are mostly 
unidentified. Determining genes and pathways, 
which are responsible for age-related survival 
changes, could facilitate the chance of novel 
therapeutic establishments. Bozdag et al. (38) 
have integrated various molecular and genetic 
methods to determine age-specific signatures 
at the genetic and epigenetic levels in glioblas-
toma multiforme. Ageing of higher organisms 
are regulated by the epigenetic variation over 
time. Some epigenetic changes do not follow 
any determined roles, suggesting that might be 
the outcome of epigenetics error accumulations. 
Thus, when this process takes place in adult stem 
cells, it could play an important role in ageing, 
through some unknown molecular mechanisms 
(39). Many researches have discussed vari-
ous mechanism that miRNA could affect DNA 
methylation as an epigenetic change contribut-
ing to ageing and cancer (Table 3). Two main 
epigenetics components are DNA methylation, 
methyl marks add to a certain bases of a gene, 
and histone modification, combination of vari-
ous molecules attached to the tails of histone 
proteins. Functionally, miRNAs could regulate 
gene expressions through two prominent mech-
anisms, including donation of the methyl group 
(40) and chromatin coiling/uncoiling (Fig.2) 
(41). Wakabayashi et al. (42) revealed that there 
is likely a cross-talk between miRNAs and epi-
genetic regulators, modulating neurogenesis in 
the adult mammalian brain. 
Fig.2: Two prominent mechanisms involved in regulation of gene 
expressions by miRs (miRNAs). 
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Table 1: Linkage between miRNA and mTOR signaling pathway
Authors Cell line(s) Type of 
disease
Type of 
miRNA
Target* Finding/Suggestion
for miRNA
Zheng et al. (27) SGC-7901 cell Gastric cancer miRNA-18a Vacuolar protein sorting-
associated protein 13D
Possible therapeutic 
strategy against 
malignancy
Wan et al. (28) CNE and HeLa 
cells
Hypoxia-
induced 
autophagy
miRNA-155 Kinesin-like protein KIF1B 
Nuclear factor 1 A-type 
A key regulator 
of autophagy via 
dysregulation of 
mTOR pathway
Shen and 
Houghton (29)
CB17SC SCID  
mice
Childhood 
sarcoma
miRNA-18a Vacuolar protein sorting-
associated protein 13D
Oncogenic 
growth signals 
may promote 
tumorigenesis by 
dampening the ATM 
checkpointmiRNA-421 Calmodulin-binding transcription activator 1
Arginine-glutamic acid 
dipeptide repeats protein 
Zhong et al. (30) Colorectal 
carcinoma cell 
Colorectal 
carcinoma
miRNA-30a FUS-interacting serine-
arginine-rich protein 1
A potential 
therapeutic target 
to block CRC 
metastasis
miRNA-30b Kinesin-like protein KIF1B 
MARCKS-related protein 
Wang et al. (31) Mouse adult 
pancreatic islets
Diabetes miRNA-7 Kinesin-like protein KIF1B 
FKBP12-rapamycin 
complex-associated protein
As a therapeutic 
target for diabetes
Li et al. (32) MG63 cells Osteosarcoma miRNA-223 AR DNA-binding protein 43 
Msx2-interacting protein 
FUS-interacting serine-
arginine-rich protein 1
Could be used in 
anticancer therapies 
in osteosarcoma
Cui et al. (33) Renal cell 
Carcinoma cell 
Renal cell 
carcinoma
miRNA-99a Uncharacterized protein 
C1orf34
plasticity related gene 1
May offer an 
attractive new 
target for diagnostic 
and therapeutic 
interventions
Iwaya et al. (34) HT29 and CaR-1 
cell 
Colorectal 
carcinoma
miRNA-144 PR domain zinc finger 
protein 2
Msx2-interacting protein
A meaningful 
prognostic marker
Gebeshuber and 
Martinez (35)
Breast cancer cell Breast cancer miRNA-100 TAR DNA-binding protein 43
Uncharacterized protein C1 
or f34
A potential target 
for therapeutic 
approaches
*; Predicted by target scan and mTOR; Mammalian target of rapamycin.
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Table 2: miRNA linking cellular senescence, ageing and cancer
Authors Type of disease Type of miRNA Target* Finding/Suggestion
for miRNA
Liu et al. (36) Ovarian carcinoma miRNA-506 Calmodulin-binding 
transcription activator 1
Msx2-interacting protein
Inhibits proliferation while 
promotes senescence
Mazan-Mamczarz 
et al. (37)
Diffuse large B cell 
lymphoma 
miRNA-520c-3p Kinesin-like protein 
KIF1B 
Nuclear factor 1 A-type 
A key regulator of autophagy 
via dysregulation of MTOR 
pathway.
Shen and 
Houghton (29)
Childhood sarcoma miRNA-18a Vacuolar protein sorting-
associated protein 13D
Oncogenic growth signals 
may promote tumorigenesis 
by dampening the ATM 
checkpoint
miRNA-421 Calmodulin-binding 
transcription activator 1
Arginine-glutamic acid 
dipeptide repeats protein
 
Zhong et al. (30) Colorectal carcinoma miRNA-30a FUS-interacting serine-
arginine-rich protein 1
A potential therapeutic target 
to block CRC metastasis
miRNA-30b Kinesin-like protein 
KIF1B 
MARCKS-related 
protein 
Wang et al. (31) Diabetes miRNA-7 Kinesin-like protein 
KIF1B FKBP12-
rapamycin complex-
associated protein
As a therapeutic target for 
diabetes
Li et al. (32) Osteosarcoma miRNA-223 AR DNA-binding 
protein 43 
Msx2-interacting protein 
FUS-interacting serine-
arginine-rich protein 1
Could be used in anticancer 
therapies in osteosarcoma
Cui et al. (33) Renal cell carcinoma miRNA-99a Uncharacterized protein 
C1 or f34
plasticity related gene 1
May offer an attractive new 
target for diagnostic and 
therapeutic intervention
Iwaya et al. (34) Colorectal carcinoma miRNA-144 PR domain zinc finger 
protein 2
Msx2-interacting protein
A meaningful prognostic 
marker
Gebeshuber and 
Martinez (35)
Breast cancer miRNA-100 TAR DNA-binding 
protein 43
Uncharacterized protein 
C1 or f34
A potential target for 
therapeutic approaches
*; Predicted by target scan and mTOR; Mammalian target of rapamycin.
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Table 3: miRNA affects DNA methylation as an epigenetic change contributing to ageing and cancer
Authors Type of disease Type of miRNA Target* Finding/Suggestion
for miRNA
Ng et al. (43) Acute promyelo-
cytic leukaemia
miRNA-34a Kelch-like protein 17 (Actinfilin)
Calmodulin-binding transcription 
activator 1
Methylation of 
miRNA-34b/c may 
contribute to APL 
leukaemogenesis
miRNA-34b Kelch-like protein 17 (Actinfilin)
Tumor protein p73 (p53-related protein)
miRNA-34c Kelch-like protein 17 (Actinfilin)
PR domain zinc finger protein 16
Xie et al. (44) Hepatocellular 
carcinoma cancer
miRNA-34a Kelch-like protein 17 (Actinfilin)
Calmodulin-binding transcription 
activator 1
DNA methylation 
might be involved 
in the inactivation of 
miRNA-34b in HCC
miRNA-34b Kelch-like protein 17 (Actinfilin)
Tumor protein p73 (p53-related protein)
miRNA-34c Kelch-like protein 17 (Actinfilin)
PR domain zinc finger protein 16
Ko et al. (3) Acute myeloid 
leukemia
miRNA-let-7a Basement membrane-specific heparan 
sulfate proteoglycan core protein 
precursor
let-7a-3 methylation 
is a positive 
prognosticator for AML 
patients
Huang et al. (45) Endometrial 
cancers
miRNA-203 Msx2-interacting protein
Macoilin
AT-rich interactive domain-containing 
protein 1A
miRNA-203 
methylation Level 
might represent a 
marker for the patients 
with endometrioid 
cancers
Verhoef et al. 
(46)
Cervical 
intraepithelial 
neoplasia grade 2 
(CIN2)
miRNA-124a-2 Arginine-glutamic acid dipeptide 
repeats protein
retinoblastoma-associated factor 600
DNA methylation 
of miRNA-124-2 on 
HPV-test-positive self-
samples is non-inferior 
to cytology triage in the 
detection of CIN2
Li et al. (47) Non-small cell 
lung cancer cells 
(NSCLC)
miRNA-503 Protein kinase C zeta type
Vacuolar protein sorting-associated 
protein 13D
Epigenetic silencing of 
microRNA-503 regu-
lates FANCA** expres-
sion in non-small lung 
cancer cell
Ben Gacem et al. 
(48)
Breast cancer miRNA-124a-1 Arginine-glutamic acid dipeptide 
repeats protein
retinoblastoma-associated factor 600
DNA methylation 
of miRNA-124a-1, 
miRNA-124a-2 and 
miR-124a-3 in breast 
cancer play a role in 
tumor growth and 
aggressiveness
miRNA-124a-2
miRNA-124a-3
Wang et al. (49) Chronic 
lymphocytic 
leukemia (CLL)
miRNA-9-3 Nuclear inhibitor of protein phosphatase 
1 
Eyes absent homolog 3
Zinc finger MYM-type protein 6
miRNA-9-3 is a tumor 
suppressor miRNA 
frequently methylated, 
and hence is silenced 
in CLL
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Table 3: Continued
Authors Type of disease Type of miRNA Target* Finding/Suggestion
for miRNA
Yamada et al. (50) Acute lymphoblastic 
leukaemia
miRNA-128a Integrator complex subunit 11 Induction of miRNA-
128a expression by DNA 
demethylation is a novel 
mechanism of resistance to 
Fas-mediated apoptosis
Nadal et al. (51) Lung 
adenocarcinoma
miRNA-34b Kelch-like protein 17 (Actinfilin)
Tumor protein p73 (p53-related protein)
Epigenetic inactivation of 
miRNA-34b/c by DNA 
methylation has independent 
prognostic value in patients 
with early-stage lung 
adenocarcinoma
miRNA-34c Kelch-like protein 17 (Actinfilin)
PR domain zinc finger protein 16
Xing et al. (52) Hepatocellular 
carcinoma
miRNA-122 Arginine-glutamic acid dipeptide repeats protein
Msx2-interacting protein
DNA Methylation of 
miRNA-122 might be 
involved in the development 
of hepatocellular carcinoma
Zhang et al. (53) Nickel-induced 
cancer
miRNA-203 Msx2-interacting protein
Macoilin
AT-rich interactive domain-containing protein 
1A
DNA methylation-
associated silencing 
of tumor suppressor 
miRNAs contributes to the 
development of Nickel-
induced cancer
Zhang et al. (54) Colorectal cancer 
(CRC)
miRNA-126 D site-binding protein
Protein LAP2
Uncharacterized protein C10orf6
DNA methylation-induced 
silencing of miRNA-126 
contributes to tumor 
invasion and angiogenesis 
in CRC
*; Predicted by target scan and **; Fanconi anemia complementation group A protein.
miRNA therapeutic applications
miRNA detection has opened a new window 
in our current perception of the gene expression 
regulation. Similar to protein-coding genes, sev-
eral investigations have been performing to deter-
mine the expression level of these small RNAs in 
vitro or in vivo. Hence, miRNAs might undergo 
gain of function (GOF) or loss of function (LOF). 
This event could play an important role in vari-
ous diseases-like protein-coding genes. Different 
mechanisms including genomic rearrangement, 
point mutation, and altering the pattern of promot-
er region methylation could be involved in regu-
lation of miRNA expressions. Besides, this type 
of RNA plays an important role in expression and 
regulation of signaling pathways. It is necessary 
to evaluate the relationship between aberrant miR-
NA, like miRNA-128 and miRNA-30, expression 
levels and notch signaling in glioma and angiogen-
esis, respectively (55). 
Several studies have shown that expression or 
inhibition of miRNAs can change the pattern of 
tumorigenesis or cancer progression (56-59). It 
has been demonstrated that expression of several 
miRNAs (e.g. miRNA-17, miRNA-155) might 
have oncogenic properties, while the others (e.g. 
miRNA-34, miRNA-16 and let-7) function as tu-
mor suppressor (60, 61). Here, we suggest that on-
cogenic or inhibitory effect of miRNAs could raise 
a distinctive point to compare the normal cells with 
different types of cancer. Thus, analysis of miRNA 
expressions, as a molecular bio-marker, could help 
diagnose the patient’s disorder stage. For example, 
over-expression of miRNA-155 and down-regula-
tion of let-7 indicated low survival chance in the 
patients with lung cancer (62, 63). Curiously, the 
expression pattern of some miRNAs is associated 
with different stages of tumorigenesis or metas-
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tasis, proposing their potential benefit to use as 
bio-markers (63). Generally, miRNAs can prevent 
cancer progression through inhibiting the other 
oncogenic miRNAs, by degrading mRNA through 
binding with miRNA, inducing tumor suppressor 
miRNAs or down-regulating the expression level 
of other miRNAs by regulating epigenetic fac-
tors, such as methylation of the gene promoter (64, 
65). In contrast, anti-sense oligonucleotides paired 
with miRNAs can reduce the expression of these 
small RNAs (66).
Discussion
Currently, there are several types of syntheti-
cally made miRNA. Antagomir is an example of 
this type of artificially made miRNAs. These RNA 
molecules are designed to inhibit miRNAs. The 
precise mechanism that anatgomir could inhibit 
miRNAs is not clear yet, although this mechanism 
might possibly be performed where these mol-
ecules could irreversibly bind to miRNAs.  miR-
NA-based therapeutics could be applied through 
two approaches; in the first approach, miRNA an-
tagonist applications (e.g. antagomir, anti-miRNA 
and LNA) contribute through GOF. In the second 
strategy, using inhibitory miRNAs (e.g. tumor in-
hibitors) could lead to LOF, compensating lack of 
natural intracellular miRNAs function. This strat-
egy is similar to transferring protein-coding genes 
into cells during gene therapy, with even less limi-
tations due to the small size of transferred DNA. 
Thus, it can easily be transferred into the cells using 
chemicals without any vector, like inhibitory RNA 
delivery. In addition, the nature of miRNA func-
tion is the other benefit which is mostly influenced 
by multiple oncogenic paths. Delivery of tumor 
suppressor miRNAs is mainly done by viral vec-
tors. Another inhibitory transmission approaches, 
direct miRNAs to the target organ using plasmids, 
transposons and cationicliposome, as monoclonal 
antibodies embedded on their surface, epigenetic 
modifying drugs such as DNA methyltransferase 
inhibitors (including 5-aza-2'deoxycytidine), his-
tonedeacetylase inhibitors (including 4-phenylbu-
tyric acid) increase the expression of miRNA by 
reducing DNA methylation and increasing histone-
acetylation level, as well as inhibiting cell prolif-
eration through reversing the tumor suppressor 
effect of miRNA (67). Thus far, several miRNA 
inhibitors have been introduced to preclinical stud-
ies in animal models, one of the most prominent 
of which is let-7 (68-70). The expression of this 
miRNA inhibitor is reduced in some cancers, lead-
ing to inhibitory effects on the RAS protein family. 
Furthermore, reduction or loss of activity of this 
miRNA inhibitor leads to increase in the expres-
sion of these proto-oncogenes (71).
These miRNAs also affect other targets such as 
MYC, cyclin D and HMG2A, indicating the im-
portance of such miRNAs in controlling several 
pathways related to cancer (72). miRNA-34a, as a 
target of P53, is another small RNA that prevents 
the growth of cancer cells by controlling the cell 
cycle (73). In addition to these direct applications 
of miRNA in cancer therapy, adjuvant administra-
tions have been discovered for these RNAs. For 
example, it has been shown that transferring and 
expressing miRNA-302 in breast cancer cells en-
hances the sensitivity of these cells to radiothera-
py (74). However, the important point, regarding 
miRNAs replacement therapy, is the risk of cel-
lular toxicity. As demonstrated, miRNAs are re-
quired to be proceeded by the RISC. Transferring 
high amounts of miRNAs to the cells can, in con-
trast, decrease or omit the other natural miRNAs 
processing by this complex, which could nega-
tively affect the cell survival. Recently in the field
of cancer and ageing, scientists claimed that uric 
acid can be used to regulate ROS, preventing can-
cer and ageing. These findings highlight the role 
of miRNA-based inhibiting the SLC2A9 antioxi-
dant pathway in cancer as a novel approach to kill 
malignant cells while a patient is fighting with the 
cancer (75).
Conclusion
The aforementioned evidences illustrate the 
complexity and the dynamic nature of miRNA-
based linkage of ageing and cancer at genomics 
and epigenetics levels that might be crucial for the 
understanding of the age-related cancer mecha-
nisms and ageing, in general.
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